Zhejiang Hisun Pharmaceutical Co., Ltd.

September 01, 2026 Bridgewater, NJ – September 1, 2026 – Hisun Pharmaceuticals USA Inc. is pleased to announce the successful U.S. launch of Fludarabine Phosphate Injection, marking another important addition to the company’s growing generic injectable portfolio in the United States. The launch represents another milestone in Hisun Pharmaceuticals USA’s continued efforts to expand its presence in the U.S. pharmaceutical market and provide patients and healthcare providers with access to high-quality, affordable generic medicines. Fludarabine Phosphate Injection is the latest addition to Hisun’s U.S. product portfolio and further strengthens the company’s capabilities and presence in the injectable pharmaceutical market. The successful launch reflects the close collaboration of Hisun’s global teams across manufacturing, quality, regulatory affairs, supply chain, and commercial operations. “Bringing a new product to the U.S. market requires strong coordination across every stage, from development and regulatory approval to manufacturing and commercialization,” said a representative of Hisun Pharmaceuticals USA. “We are proud to achieve this milestone and remain committed to expanding our portfolio to better serve the needs of the U.S. healthcare market.” Hisun Pharmaceuticals USA will continue to leverage its global manufacturing capabilities and local market expertise to introduce additional pharmaceutical products in the United States and build sustainable partnerships with customers and healthcare stakeholders. Passion for Life, Light for Health. About Hisun Pharmaceuticals USA Hisun Pharmaceuticals USA Inc., based in Bridgewater, New Jersey, is the U.S. subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. The company is focused on bringing high-quality pharmaceutical products to the U.S. market and developing long-term partnerships across the healthcare industry.

Insilico Medicine announced Tuesday a series of collaborations with China Medical System (CMS) spanning multiple projects in central nervous system (CNS) and autoimmune diseases. The deal pairs the companies' capabilities across the drug development lifecycle, with the aim of moving therapies from research into clinic more quickly. Under the agreement, the companies will develop at least two R&D programmes, with Insilico set to receive up to "several tens of millions of HKD" – roughly $2.5 million to $9 million – in funding per programme. Insilico will provide its Pharma.AI platform, which uses multi-omics data to identify and prioritise disease targets, along with generative chemistry tools to design new molecules and predictive models powered by large language models. CMS will contribute clinical and regulatory expertise, as well as trial execution capabilities, to help advance programmes from preclinical research into the clinic and toward commercialisation. "Under this collaboration framework, we look forward to leveraging resource sharing and joint decision‑making to significantly shorten the development cycle of high‑potential innovative drugs, enhance translational efficiency and clinical success rates, and accelerate the journey of more innovative molecules from 'proof of concept' to truly 'benefiting patients,'" said Feng Ren, co-CEO and chief scientific officer at Insilico Medicine. According to Insilico, its AI and automation technologies have reduced preclinical candidate nomination timelines from an average of 4.5 years to 12 to 18 months per programme. Between 2021 and 2024, the company nominated 20 preclinical candidates by synthesising and testing 60 to 200 molecules per programme. "Insilico Medicine's leadership in AI drug discovery platforms and data-driven R&D is strategically complementary to CMS' capabilities in innovative R&D and clinical translation," said Lam Kong, chairman, CEO, president and executive director at CMS. Looking ahead, the partners plan to expand collaboration across pipeline planning, clinical strategy and global partnerships, Ren said. The CMS tie-up follows a string of recent milestones for Insilico. In late 2025, the company listed on the Hong Kong Stock Exchange. It later announced its first preclinical candidate from a collaboration with Hisun Pharmaceutical and signed additional partnerships with Servier in oncology, Hygtia Therapeutics in CNS diseases and Qilu Pharmaceutical Group in cardiometabolic drug development.

Insilico Medicine linked up with Qilu Pharmaceutical Group and its Shanghai Qilu Pharmaceutical Research Center subsidiary on Tuesday to find small molecule treatments for cardiometabolic diseases using AI. It's the latest in a line of January deals from the AI firm, which made its public debut on the Hong Kong Stock Exchange at the end of December. Insilico signed an oncology-focused discovery collaboration with Servier worth up to $888 million, and also snagged an NLRP3 inhibitor from Hygtia Therapeutics for $10 million upfront. And as part of its partnership with Hisun Pharmaceutical, Insilico nominated a preclinical candidate just eight months after the pair began working together. From PandaOmics to Pharma.AITuesday's deal builds on Qilu and Insilico's existing relationship; since 2021, the Chinese company has used Insilico's AI-driven PandaOmics platform for target and biomarker discovery. "This collaboration marks a deepening of our partnership, evolving from initial software licensing to in-depth, R&D collaboration," said Weikang Tao, the group vice president and head of global R&D at Qilu Pharmaceutical Group. Under the new drug development agreement, Insilico will use its Pharma.AI platform — which encompasses end-to-end generative Al and automation technologies — to design and optimise small molecule inhibitors. "I believe that strategies targeting cardiometabolic diseases have the potential to generate the first drugs to achieve large-scale healthspan extension, and I look forward to AI technology accelerating innovation in the field and maximizing potential," said Alex Zhavoronkov, Insilico's founder, CEO and chief of business. Further development of the candidates, as well as commercialisation, will fall under the purview of Qilu Pharmaceutical. The deal is valued at close to $120 million, including development and commercialisation milestones, plus single-digit royalties.